TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT05583448

Intervention type: DEVICE
Intervention: ExploR Radial Head
Description: Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication.
Study: NCT05912062

Intervention type: DRUG
Intervention: Paclitaxel (neoadjuvant)
Description: Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks
Study: NCT06789302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT2-SCT intravenous infusion
Description: DT2-SCT is an investigational therapy using autologous adipose-derived mesenchymal stem cells (MSCs) prepared from each participant's adipose tissue. MSCs are isolated from approximately 50 mL of adipose tissue obtained through a tumescent liposuction procedure. The cells are expanded, tested for contaminants, and suspended in a sterile, cryopreservation-free medium (Plasma-Lyte A) for administration.~The intervention involves a single intravenous infusion of DT2-SCT at a dosage of 1 x 10\^6 MSCs/kg body weight, delivered over a period of one hour. Participants will be closely monitored for at least two hours post-infusion to assess immediate safety and potential adverse effects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group (Group B) will receive a single intravenous infusion of Plasma-Lyte A, a sterile, isotonic, non-pyrogenic crystalloid solution. The infusion will be administered in a volume of 100 mL over a period of one hour.
Study: NCT06785090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) formulated as a 0.09% ophthalmic solution. It is administered to reduce inflammation and prevent cystoid macular edema (CME) following cataract surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Description: antibiotic, standard postoperative care regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5% ophthalmic solution
Description: antibiotic, standard postoperative care regimen
Study: NCT06577935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2118
Description: Subcutaneous injection
Study: NCT05882734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1774
Description: In Phase 1b, M1774 will be administered as dosing regimen 1 or dosing regimen 2 until disease progression, death discontinuation criteria or any other reason. The selected dosing regimen of M1774 will be administered in all arms of Phase 2a.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab will be administered as an intravenous infusion every 3 weeks in all arms of Phase 1b and Phase 2a until disease progression, death discontinuation criteria or any other reason.
Study: NCT06315751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemlapodect
Description: Gemlapodect is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of tics associated with TS. Administered in the form of oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered in the form of oral capsules with inert ingredients.
Study: NCT05495243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARINA-1
Description: ARINA-1 (88 mg/mL ascorbic acid, ASC; 150 mg/mL reduced glutathione, GSH)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline (0.9%)
Study: NCT06785090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Description: steroid, standard postoperative care regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate 0.1%
Description: steroid, standard postoperative care regimen
Study: NCT06790043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-selected visual art in hospital room
Description: Patient-selected visual art placed in patient's antepartum hospital room

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Patient will receive routine care, and will not select, nor have, visual art in their antepartum hospital room.
Study: NCT06789055

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Spray
Description: Before the capillary blood glucose measurement, cold spray will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.

Intervention type: OTHER
Group type: OTHER
Intervention: Cold Spray
Description: Before the capillary blood glucose measurement, cold spray will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Before the capillary blood glucose measurement, placebo will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Before the capillary blood glucose measurement, placebo will be applied to the measurement site from a distance of 30 cm for 10 seconds. Following this, the area will be cleansed with an antimicrobial swab for 10 seconds using a circular motion, starting from the center and moving outward. Subsequently, the fingertip will be punctured with a lancet to obtain a blood sample. The first drop of blood will be wiped away with cotton, and the glucose measurement will be performed using the subsequent drop utilizing the Standard GlucoNavii GDH device. The patient will then be asked to assess their pain during the procedure using the Visual Analog Scale (VAS) for pain evaluation.
Study: NCT05766657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiome-targeted diet
Description: The gut microbiota (on stool) and metabolic profile (on stool and urine) will be analyzed at time 0, and the dietary plan will contain specific directions aimed at restoring a proper metagenomic and metabolomic profile of the microbiota.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual care diet
Description: Subjects on the control group will receive general dietetic advice for Obesity or T1D
Study: NCT05970484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DrinksRation
Description: DrinksRation (www.drinksration.app; formerly called InDEx) app was developed following the Medical Research Council Complex Intervention Guidelines and using a co-design methodology. It was developed by the King's Centre for Military Health Research (King's College London) and Lancaster University, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app was designed to support veterans drinking at a hazardous or harmful level by providing bespoke advice and support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BeAlcoholSmart
Description: BeAlcoholSmart is a progressive web app (PWA). The app can take advantage of smartphone features such as push notifications and haptics without requiring the participant to download via an app store. The app will contain a 7-day alcohol unit calculator and generic public health guidance on safe drinking. Participants will also receive reminders via email prompting them to consult the guidance as part of the BeAlcoholSmart. Control participant participants will be invited to complete all questionnaires via Qualtrics, with an email reminder being sent when they are due.
Study: NCT05378035

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Tests
Description: Eligible subjects will receive additional blood tests for determination of DOAC levels and pharmacogenomic studies. Participants shall undergo DOAC level testing at peak, trough, 24, and 48 hours after discontinuation of DOAC for elective medical procedures. We shall also record their baseline demographics, clinical assessments, medical comorbidities, blood parameters, and concurrent medications. We shall minimize the blood taking by combining DOAC levels and blood tests essential for routine medical consultation and pre-procedural workup. Blood taking will only be performed by clinicians or phlebotomists who are experienced in the procedure.
Study: NCT06454136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTX-207
Description: Experimental Pscyhoeducation and Intervention App

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Comparator App + Treatment as Usual (TAU)
Description: Digitized content and information included in standard of care (i.e., TAU)
Study: NCT04903522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baroque music listening
Description: Patients will listen to a 30-minute musical path of baroque pieces. Before and after this, anxiety, depression and consciousness fluidity will be evaluated thanks to different questionnaires
Study: NCT05678348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Patients will be instructed to take their dose at approximately the same time each day.
Study: NCT05435495

Intervention type: PROCEDURE
Intervention: Single-photon emission computed tomography
Description: Imaging procedure

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Blood draw for future research tests (45-60 mL).

Intervention type: PROCEDURE
Intervention: Tumor Biopsy
Description: Guided biopsy of lesion
Study: NCT05614024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real fNIRS Neurofeedback
Description: Participants will be instructed to use real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Control fNIRS Neurofeedback
Description: Participants will be instructed to use sham real-time fNIRS neurofeedback to non-invasively regulate neural activation associated with symptoms in individuals with bulimia nervosa. During the training, participants will view images on a computer screen, listen to sounds, and consume a shake.
Study: NCT06229418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DFR AED Pilot Program
Description: Integrate AED drone delivery into an existing FAA-approved drone-as-first-responder programs
Study: NCT04757519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP-GLB Standard
Description: The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP-GLB Enhanced
Description: The intervention is based upon the 2017 version of the University of Pittsburgh DPP Group Lifestyle Balance Program (DPP-GLB). Participants will receive the DPP-GLB intervention once per week for 12 weeks, then twice monthly for 12 weeks (18 sessions total). The program includes hour-long group-based sessions and supportive materials including a weekly food diary and FitBit/pedometer. Intervention week 4, weight loss non-responders defined as weight loss less than 1% receive weekly telephone intervention, using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Additionally, this intervention includes weekly phone calls using motivational interviewing techniques to provide social support, assess barriers, resolve ambivalence, and support the participant in developing personal strategies. Links to relevant videos may also be provided.
Study: NCT04512547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129XeMRI
Description: Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized 129XeMRI
Description: Images obtained using 129XeMRI will be obtained on both obese asthmatic and non-asthmatics
Study: NCT05417100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: methadone 0.2 mg/kg IV.
Study: NCT05303467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere GBM
Description: Single treatment of TheraSphere GBM device
Study: NCT05906511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol 5 MG
Description: Dronabinol 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 10 MG
Description: Dronabinol 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Purified THC in an ethanolic solution
Description: 2mg Purified THC in an ethanolic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Purified THC in an ethanolic solution
Description: 4mg Purified THC in an ethanolic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo and/or vaporized saline
Study: NCT04859946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study: NCT05771428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-552
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-552
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-552
Description: Oral Capsule
Study: NCT05919160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBC (Diagnostic Biochips) Deep Array microelectrode; Intan Electrophysiology recording system; Matlab response recording to behavioral task
Description: Devices listed are components of a single intervention that includes: Record neuronal activity (Intan) from electrodes (DBC), record and analyze patient responses (Matlab)
Study: NCT05748171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved in several countries for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALLR3
Description: The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase \[or erwinia-asparaginase in the event of an allergic reaction to PEG-asparaginase\]) has been adopted by pediatric oncology groups as treatment for pediatric relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)
Study: NCT05771428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-552
Description: Oral Capsule
Study: NCT05519696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants receiving the intervention will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting and includes a focus on cultural topics related to collectivism. Participants receive FitBits to track their physical activity and through the FitBit mobile app are connected to their group members to encourage communication and social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Participants receiving the comparison program will complete a 10-week group program. Group sessions meet once per week for 2 hours and include three components - discussion-based health promotion initiative, group walking program, and individual-based goal-setting and behavioral skills training. The health promotion initiative uses cultural targeting only (and no focus on collectivism). Participants receive FitBits to track their physical activity, but are not connected to their group members on the mobile app.
Study: NCT05218213

Intervention type: OTHER
Intervention: No intervention
Description: Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)
Study: NCT05220657

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value

Intervention type: DIAGNOSTIC_TEST
Intervention: Maximal incremental exercise test
Description: Gas exchanges are measured during all the test on ergocycle until oxygen consumption reach its maximum value
Study: NCT05218213

Intervention type: OTHER
Intervention: No intervention
Description: Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)

Intervention type: OTHER
Intervention: No intervention
Description: Assessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.~1. Dual-task walking with the auditory stroop task.~2. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right~3. Navigational and dual-task walking (condition 1 and 2 together)
Study: NCT04815096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
Description: \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
Study: NCT04515836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
Study: NCT04701307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given IV